chrisvoncsefalvay/vaers-outcomes huggingface dataset:
STOMACH PAIN; SWEAT; DIZZY; CHILLS; JOINT ACHES; FEVER; HEADACHES; MUSCLE ACHES; FATIGUE; This spontaneous report received from a patient concerned a 63 year old female. The patient's weight was 140 pounds, and height was 60 inches. The patient's concurrent conditions included lupus, rheumatoid arthritis, diabetes, latex allergy, non alcoholic, and non smoker, and other pre-existing medical conditions included no drug abuse or illicit drug usage. The patient received covid-19 vaccine  (suspension for injection, route of admin not reported, batch number: 203A21A, and expiry: UNKNOWN) dose was not reported, administered on 24-MAY-2021 for prophylactic vaccination. Concomitant medications included hydromorphone for drug used for unknown indication. On 24-MAY-2021, the subject experienced sweat. On 24-MAY-2021, the subject experienced dizzy. On 24-MAY-2021, the subject experienced chills. On 24-MAY-2021, the subject experienced joint aches. On 24-MAY-2021, the subject experienced fever. On 24-MAY-2021, the subject experienced headaches. On 24-MAY-2021, the subject experienced muscle aches. On 24-MAY-2021, the subject experienced fatigue. On 25-MAY-2021, the subject experienced stomach pain. Laboratory data (dates unspecified) included: Body temperature (NR: not provided) highest was101F. Treatment medications (dates unspecified) included: ibuprofen. The action taken with covid-19 vaccine was not applicable. The patient had not recovered from fever, muscle aches, stomach pain, headaches, fatigue, chills, and sweat, and the outcome of joint aches and dizzy was not reported. This report was non-serious.
allergy: nuts, dairy - anaphylaxis  Hx: asthma  Not pregnant  Patient was found sitting on ground with swollen face, lips, and hives on bilateral arms, back, chest and abdomen. Patient is aox4. Patient already took 50mg PO Benadryl and used her albuterol. Partner at side. Patient stated she had a sandwich about an hour and a half before that might've cause allergic reaction. Patient does carry an epi pen, but not today. 1230 bp 100/60 hr 97 o2sat 99%. 50mg IM benadryl administered  to left arm at 1230. 1240 hr 120, o2 sat 99%> No relief and now patient is coughing, 0.5 mg epi im to left arm. Laid patient down. Ems called. Patient remains conscious and alert. Noted she was feeling better before EMS arrived.
Symptoms: metalic taste in mouth, jittery, mild nausea.  Signs: Vital Signs normal and stable.  Everything else normal.Time: 30 min.  Treatment: watch and wait.
began shivering; This is a spontaneous report from a non-contactable consumer.  A 86-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), via an unspecified route of administration on 25Jan2021 at 09:00 (at an unknown age) as a single dose for COVID-19 vaccination. Medical history was not reported. Concomitant medications were not reported.  On 25Jan2021 at 16:30, the patient began shivering. Putting on another layer of clothing alleviated the problem. It was also reported that the patient's husband had forgotten to turn up the heat that morning so the house was colder than usual. The clinical outcomes of shivering was unknown.   No follow-up attempts are possible; information about lot number cannot be obtained.   No follow-up attempts are possible. No further information is expected.
about 2" diameter round raised and red rash on left arm. Had the shot 8 days ago. It just started to itch and burn
Patient received Pediarix (DTaP/Hep B/IPV) and IPV and DTaP on 7/11/07. She had a few scattered 2-3mm hives while crying after vaccines, which faded after a few minutes. History of similar hives in other situations. Inadvertent administration of dose noted when returned for Prevnar vaccine (Pediarix had been given instead of Prevnar dose)
Patient reports that she has had redness and pain at the injection sight for over 1 week. Patient returned to the clinic to have arm assessed. No redness noted and no swelling at injection sight. Patient did say injection sight was tender to  touch.
really sore; This spontaneous case was reported by a nurse and describes the occurrence of PAIN (really sore) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 11-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In 2021, the patient experienced PAIN (really sore). In 2021, PAIN (really sore) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was reported. It was reported that the patient had soreness after his 1st dose on 11-Jan-2021. Each time pain lasted 1 day No treatment information was reported.   This case was linked to MOD-2022-589106 (Patient Link).
Initial report received from a nurse on 16 Feb 2011: This patient was vaccinated with MENVEO (batch number A100028) 0.5 ml dose, intramuscularly on 07 Feb 2011. The patient received MENVEO lyophilized powder reconstituted with saline instead of liquid conjugate component 07 Feb 2011. No other information reported. Follow- up report received from a nurse on 08 Mar 2011: Patient demographic updated. This patient was vaccinated with MENVEO into deltoid.
Patient reports a burning sensation throughout his entire body for 5+weeks, states feels like he has a mild/moderate sunburn. No rash, redness or lesions anywhere Narrative: Patient is going to dermatolgist
Pt developed a blotchy-type rash all over her body which appeared a couple of days, post vax. Treated with Benadryl and instructed to follow-up if no improvement.
Swelling of the lips (inside mouth); Swelling of cheeks (inside mouth); Dry mouth (inside mouth and forward to lips); Cracked lips; Extremely dry lips; Abnormal hair growth around mouth; Emergence of black hair in beard when previously white; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6198), via an unspecified route administration in the left arm on 02Mar2021 at 11:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Relevant medical history included high blood pressure and obese (obesity). Concomitant medication was not reported. The patient did not have any allergies to food, medications, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04Mar2021, the patient experienced swelling of the lips and cheeks (inside mouth), dry mouth (inside mouth and forward to lips), cracked and extremely dry lips and abnormal hair growth around mouth (new hair along lip line and emergence of black hair in beard when previously white). No treatment was received for the events experienced. The events did not result in a doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcomes of the events swelling of the lips, swelling of cheeks, dry mouth, cracked lips, extremely dry lips, abnormal hair growth around mouth and emergence of black hair in beard were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Very high fever, acute pain all over body, chills, headache, nasal congestion, fatigue, weakness.  Began approximately 10 hours after receiving vaccine.  Lasted 24 hours from adverse onset.  Fatigue and weakness continue.
Thirst; Injection site soreness; This spontaneous case was reported by a consumer and describes the occurrence of THIRST (Thirst) and VACCINATION SITE PAIN (Injection site soreness) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027B21A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure high and Heart rate high (patient stated that sometimes her heart goes a little faster). Concomitant products included ATORVASTATIN, METOPROLOL SUCCINATE, LEVOCETIRIZINE and ACETYLSALICYLIC ACID (BAYER ASPIRIN) for an unknown indication.    On 10-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Apr-2021, the patient experienced THIRST (Thirst) and VACCINATION SITE PAIN (Injection site soreness). On 11-Apr-2021, THIRST (Thirst) and VACCINATION SITE PAIN (Injection site soreness) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.    Treatment information was not provided.   This case was linked to MOD-2021-124783, MOD-2021-125294 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 12-May-2021: Initial additional 1 received, no newinformation(NNI) On 16-Jun-2021: Initial additional 2 received, Updated reporter details. Added patient height, weight, race, ethnicity, other relevant history. Updated anatomical location of vaccine, Action taken, dechallenge & rechallenge, vaccine facility information. Added concomitant medications. Updated outcome of events to resolved and product - event details tab.
Almost immediately after  the vaccine, from the right side corner of my mouth to the middle of my lip went numb.  I also experienced slight numbness down my right arm and a fleeting stiff neck.  The numbness to my lip lasted until the early evening at which time I suffered an ocular migraine.
CHILD UNDER AGED AT TIME OF VACCINE. DOB LISTED AS 06/11/2021 ON CONSENT. IMMTRAC LISTS AS 6/11/2010.
Client reported dizziness and tingling in the face. BP @ 01:05  153/98 pulse 88.  After resting client stated she felt "better".  BP repeated at 01:20  143/92 pulse 83.  Encouraged client to contact PCP for any adverse reactions.
This spontaneous report was received from a licensed practical nurse concerning a patient of unknown age and gender. There was no information about the patient's pertinent medical history, concurrent conditions, concomitant medications and drug reactions/allergies. On an unknown date, the patient was going to be vaccinated with the second dose M-M-R II, subcutaneously (lot number L046506 and expiration date 17-MAY-2017) for prophylaxis (dose was not reported). However, the patient missed the dose because the product was found unfit for use and needed replacement. A product quality complaint was done. No adverse event was reported and no further information was provided. Additional information has been requested.
This case was reported by a physician and described the occurrence of discomfort in a male patient who received FLUARIX TETRA. On an unknown date, the patient received FLUARIX TETRA. On an unknown date, unknown after receiving FLUARIX TETRA, the patient experienced discomfort. On an unknown date, the outcome of the discomfort was unknown. It was unknown if the reporter considered the discomfort to be related to FLUARIX TETRA. Additional details were provided as follows: The age at vaccination was not reported. No more local discomfort than after flu jab. This case has been linked with case US2018GSK032395 and US2018GSK032396, reported by the same reporter.
Patient was at nursing facility we gave strict instructions to nursing staff to have all paperwork available to give correct covid bivalent to patients living there she was on their list of needing booster and they stated she had not had a booster. Nursing staff reports that family member of patient gave verbal consent for patient receive booster as she has not received it. After booster was given hard copy was brought and she had a Bivalent booster vaccine 2 months ago which was not a 2nd covid vaccine but a Bivalent on 9/27/22   lot# gh9702.  We were informed after of previous bivalent given. We contacted our Health Office to inform him of error and asked nursing staff at facility to notify patients family. Representative verbalized understanding and stated that she would contact patients' family.
Red, swollen, hot (emitting heat) worst first 24 - 48 hrs. Decreased by 72 hours but still slightly warm after.
flu like symptoms for 2 days; This case was reported by a consumer via interactive digital media and described the occurrence of influenza-like symptoms in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced influenza-like symptoms. On an unknown date, the outcome of the influenza-like symptoms was recovered/resolved.   The reporter considered the influenza-like symptoms to be related to Shingles vaccine.  Additional details were provided as follows: The patient self-reported this case. The age at vaccination was not reported. The patient had flu like symptoms for 2 days from the second Shingles shot. The patient stated that definitely did not want to get the shingles. The follow-up would not possible as no contact details were available.
Initial report received from a non-healthcare professional (patient) on 16 October 2012. A 64-year-old female patient, who had no illness at the time of vaccination and had concomitant medication with eye drops, had received an intramuscular dose of FLUZONE (Lot number unknown, dose number and site of vaccination not reported) on 29 September 2012. On 06 September 2012 i.e. 07 days after vaccination administration the patient's left arm started to feel sore and had flu symptoms and a high fever of 101 F. The patient had gone to the pharmacy to show them that the arm was swollen and she was told to put ice pack on it. There was a goose egg size lump at the injection site which she noticed after she put the ice on it. The next day a water blister appeared at the injection site and it was red and swollen. The patient soaked a needle in alcohol and stabbed the water blister and put Polysporin on it. Laboratory details were not reported and corrective treatment includes ibuprofen and polysporin. As of 16 October 2012, the patient had not recovered. Documents held by sender: none. Follow up information received from a healthcare professional on 31 January 2013. The patient received FLUZONE in left deltoid from lot number UH716AB. Approximate size of lump at the injection site was reported as 2 inch long, 1 inch wide and 3/4th inch high.
Waited the 15 minutes for monitoring. Became wheezy when walking to truck. Did have cough immediately after vaccine was administered. Patient is asthmatic. Held for 30 additional minutes for monitoring with no symptoms. Lung sounds clear. No medications administered.
Minor skin irritation; Tiny dot/bump; This spontaneous case was reported by a consumer and describes the occurrence of SKIN IRRITATION (Minor skin irritation) and PAPULE (Tiny dot/bump) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced SKIN IRRITATION (Minor skin irritation) and PAPULE (Tiny dot/bump). At the time of the report, SKIN IRRITATION (Minor skin irritation) and PAPULE (Tiny dot/bump) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications details were not reported by the reporter. Treatment details was not reported by the reporter.; Sender's Comments: Very limited information regarding these events has been provided at this time.  Further information has been requested.
Extremely tired, headache for 24 hours, loss of appetite & fever for 8 hours ....Highest fever went was 100.1 ....Would do it again !!!! Worth it to be protected from a deadly infection of Covid 19 !!!!
Reported completed by wife: He was rushed to the hospital on March 01, 2021 and was released from the hospital and sent to rehab at a different hospital (PRIVACY) due to oxygen levels being low. When he went to rehab, his symptoms declined and they sent him by ambulance back to the hospital where he passed away May 27, 2021. He was in hospital hospice ward at the time. He was in the hospital for 14 days the first and the 2nd time he died.
Administered vaccine patient then c/o dizziness, ABD pain, nausea and broke out in hives trunk area. Gave Diphenhydramine 25mg IM RA. Pt shaky, nervous, crying, after 1 hr of observation. Rash decreased by 80%. Patient felt better went home with father.
Patient came in Friday 10/8/21 at around 1030 for her yearly influenza vaccine. She had minimal arm soreness on Friday evening. On Saturday she noted that her arm was quite red, warm, and painful and was swollen "the size of a baseball". She did take a Benadryl that evening at the advice of her daughter which did help her sleep. On Sunday morning, her arm was still warm and red with some swelling but the swelling was improved. On Monday, her arm is still slightly red and slightly warm but overall much better. Patient never had systemic reaction just localized reaction. She will call if symptoms worsen or do not resolve.
This spontaneous report as received from a health care worker (also reported as medical assistant) refers to an unspecified number of patients of unknown age and gender. Information regarding relevant medical history and concurrent condition were not reported. Since 12-OCT-2015, the patients were vaccinated with improperly stored ROTATEQ (lot # L004466, expiration date 02-AUG-2016, oral, dose not reported). No adverse effects reported. This is one of several reports received from the same source. Additional information has been requested.
This spontaneous report as received from a pharmacist refers to 1 unspecified infant of unknown age and gender. The patient's concurrent conditions and medical history were not reported. On 05-JUL-2015, the patient was vaccinated with a dose of improperly stored RECOMBIVAX HB (dose and route of administration were not reported, lot number K010535 and expiration date 27-AUG-2016 or lot number K020216 and expiration date 17-SEP-2016). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
18yo vaccinated w/MMR was pregnant of time of vax was hospitalized & a therapeutic abortion was performed;
Patient underage for vaccine provided. No symptoms presented during observation period no report from family post vaccination. Discovered by billing team.
Administration error - patient received 2nd dose of Moderna 1 week after 1st dose.
high pitch scream for 1hr, 2hr p/vax;starting 62hr p/vax loss of tongue control & sudden onset of extreme drooling this lasted 6-8wk;high fever for 48hr, starting 7 days p/vax;
Employee received MMR on 12/07/2000 at the employer health center. On 03/22/2002 he called the center to report that 1 month after the vaccination he began having inflammatory polyarthritis which still persists. He is being prescribed Prednisone, Vioxx, and plaquinil.
Feeling intense sensation like "jackhammering in every joint"; Exhausted; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (Feeling intense sensation like "jackhammering in every joint") and FATIGUE (Exhausted) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Oct-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Oct-2021, the patient experienced ARTHRALGIA (Feeling intense sensation like "jackhammering in every joint") and FATIGUE (Exhausted). On 31-Oct-2021, ARTHRALGIA (Feeling intense sensation like "jackhammering in every joint") and FATIGUE (Exhausted) had resolved.            No concomitant medication reported. No treatment information was provided.  Patient stayed home to rest all day, and reported symptoms were cleared by 31-OC-2021.
Heart palpitations; Blood pressure was high 192/110; Increased pulse rate; This spontaneous case was reported by a consumer and describes the occurrence of PALPITATIONS (Heart palpitations), HYPERTENSION (Blood pressure was high 192/110) and HEART RATE INCREASED (Increased pulse rate) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025J20A) for COVID-19 vaccination.     Concurrent medical conditions included Cholesterol. Concomitant products included ATORVASTATIN CALCIUM (LIPITOR) for Cholesterol.    On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Jan-2021, the patient experienced PALPITATIONS (Heart palpitations), HYPERTENSION (Blood pressure was high 192/110) and HEART RATE INCREASED (Increased pulse rate). At the time of the report, PALPITATIONS (Heart palpitations), HYPERTENSION (Blood pressure was high 192/110) and HEART RATE INCREASED (Increased pulse rate) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 05-Jan-2021, Blood pressure measurement: 192/110 mmHg was high 192/110.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.